Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 05

1271P - Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC

Date

14 Sep 2024

Session

Poster session 05

Topics

Targeted Therapy;  Molecular Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Hakan Bozcuk

Citation

Annals of Oncology (2024) 35 (suppl_2): S802-S877. 10.1016/annonc/annonc1602

Authors

H. Bozcuk1, L. sert2, M.A. Kaplan3, A.M. Tatli4, M. Karaca4, B. Kilictas5, M. Artac5, M.A.N. Sendur6, B. Bilgin7, S. Balli8, A. Demirkazik9, S. Kilickap10, H. Taban11, H.G. Güzel12, M. Kocer12, B. Koylu13, F.S. Biricik13, G. Karakaya14, H.S. Coskun14, M.S. Alemdar15

Author affiliations

  • 1 Medical Oncology, Private Practice, 07160 - Antalya/TR
  • 2 Medical Oncology, Dicle University Medical Facultiy, 21080 - Diyarbakir/TR
  • 3 Medical Oncology Department, Dicle University, 21280 - Diyarbakir/TR
  • 4 Medical Oncology Department, Akdeniz University - Faculty of Medicine, 07070 - Antalya/TR
  • 5 Medical Oncology Dept., Necmettin Erbakan University - Meram Medical Faculty, 42080 - Konya/TR
  • 6 Medical Oncology Department, Ankara Yildirim Beyazit Universty - Faculty of Medicine, 6800 - Ankara/TR
  • 7 Medical Oncology Dept., Ankara Yildirim Beyazit Universty - Faculty of Medicine, 6800 - Ankara/TR
  • 8 Department Of Medical Oncology, Ankara University - Faculty of Health Sciences, 06100 - Ankara/TR
  • 9 Medical Oncology Dept, Ankara University Medical School - Cebeci Hastaneleri Tibbi Onkoloji, 06590 - Ankara/TR
  • 10 Medical Oncology Department, Istinye University Faculty of Medicine, 34408 - Kâğıthane/İstanbul/TR
  • 11 Medical Oncology, VM Medical Park Ankara (Keçiören), 06120 - Ankara/TR
  • 12 Uncali Mahallesi, Toroslar Caddesi No.21 B, Blok Daire.10, Antalya Training and Research Hospital, 07100 - Antalya/TR
  • 13 Medical Oncology, Koç Üniversitesi Hastanesi, 34010 - Istanbul/TR
  • 14 Medical Oncology Department, Antalya Özel ASV Yaşam Hastanesi, Antalya/TR
  • 15 Medical Oncology, Medical Park Antalya Hastanesi, 07160 - Antalya/TR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1271P

Background

Understanding the associates and causes of progression after first-line treatment in EGFR-mutant advanced NSCLC remains a critical yet elusive endeavor. In this study, we employed a comprehensive approach integrating machine learning classification and causal inference analysis to unveil the determinants of progression in this patient cohort.

Methods

Retrospective data from eleven academic centers were gathered to compile a cohort of EGFR mutant patients. Classical patient features, treatment characteristics, and the neutrophil to lymphocyte ratio (NLR) at the onset of first-line treatment were analyzed. Fifteen machine learning algorithms were employed to identify the optimal model, evaluated based on F1 score and area under the curve (AUC). Additionally, Linear Non-Gaussian Acyclic Model (LINGAM) was utilized for causal inference analysis to delineate the causal relationships driving progression.

Results

Among 333 patients initially evaluated, 205 cases were deemed suitable for machine learning analysis after accounting for missing data and follow-up duration. Linear discriminant analysis emerged as the most accurate model, achieving an AUC of 0.74 and an F1 score of 0.77. The top three influential variables identified by this model were smoking status, NLR category, and type of first-line treatment with variable importance scores of 1.2, 0.8, and 0.6, respectively. Moreover, LINGAM analysis revealed NLR category, smoking status, and gender as causal factors for progression, with causal estimate scores of -0.20, -0.17, and -0.04, respectively.

Conclusions

This study represents a pioneering effort in utilizing machine learning to explore the determinants of progression after first-line treatment in EGFR-mutant, advanced NSCLC. Our findings underscore the roles of smoking status, NLR category, and type of first-line treatment in driving progression. Furthermore, the causal inference analysis sheds light on smoking status, NLR category, and gender as causally significant factors. This understanding paves the way for elucidating the pathogenesis and developing novel therapeutic strategies for EGFR-mutant advanced NSCLC.

Clinical trial identification

Editorial acknowledgement

During the preparation of this work the authors used ChatGpt 3.5 in order to enhance readibility. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.